TABLE 9Study characteristics of the included economic evaluations

Kuehne and colleagues 200264Campos and colleagues 200765
Publication year20022007
CountryUSAUSA
Study typeCUA modelCEA model
Study populationA cohort of HCV/HIV co-infected individualsA treatment-eligible urban cohort, co-infected with HCV/HIV
Interventions
  1. IFN α (48 weeks)
  2. IFN α and RBV (24 and 48 weeks)
  3. PEG α (48 weeks)
  4. PEG α and RBV (48 weeks)
  1. PEG α-2a and RBV (48 weeks)
  2. IFN α-2a and RBV (48 weeks)
  3. PEG α-2a (48 weeks)
Treatment effect modelledPatients were assumed to have:
  1. No treatment response: received no clinical benefit and were subject to their annual pretreatment risk of HCV-related liver disease progression
  2. Partial but non-sustained response: did not progress in their HCV-related liver disease during treatment but were subject to pretreatment risks of liver disease once treatment was stopped
  3. Patients with a sustained response (i.e. undetectable HCV RNA for > 6 months after treatment) did not experience a future risk of HCV-related liver disease
SVR (in combination PEG α-2a and RBV) of 40%, based on one trial66
Currency baseUS$2004, US$

CEA, cost-effectiveness analysis; CUA, cost–utility analysis; IFN α, interferon alfa; PEG α, peginterferon alfa; RBV, ribavirin.

From: 5, Economic analysis

Cover of Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation
Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.17.
Hartwell D, Jones J, Baxter L, et al.
Southampton (UK): NIHR Journals Library; 2011 Apr.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.